Ayrton Capital LLC Pharma Cyte Biotech, Inc. Transaction History
Ayrton Capital LLC
- $2.64 Million
- Q3 2023
A detailed history of Ayrton Capital LLC transactions in Pharma Cyte Biotech, Inc. stock. As of the latest transaction made, Ayrton Capital LLC holds 92,087 shares of PMCB stock, worth $192,461. This represents 7.31% of its overall portfolio holdings.
Number of Shares
92,087
Previous 276,992
66.75%
Holding current value
$192,461
Previous $792,000
75.63%
% of portfolio
7.31%
Previous 26.3%
Shares
5 transactions
Others Institutions Holding PMCB
# of Institutions
32Shares Held
1.07MCall Options Held
5.4KPut Options Held
400-
K2 Principal Fund, L.P. Toronto, A6328KShares$684,4810.27% of portfolio
-
Geode Capital Management, LLC Boston, MA200KShares$418,5870.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA175KShares$364,9180.0% of portfolio
-
Equitec Proprietary Markets, LLC82.7KShares$172,8990.12% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny43.8KShares$91,5420.0% of portfolio
About PharmaCyte Biotech, Inc.
- Ticker PMCB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,750,100
- Market Cap $43.4M
- Description
- PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...